ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: For example, BCR‐ABL rearrangement mutations are related to the efficacy of small molecule inhibitors of the BCR‐ABL kinase, which leads to the wide usage of imatinib in the treatment of chronic myeloid leukemia.9